Swedish National Guidelines on Urothelial Carcinoma: 2021 update on non-muscle invasive bladder cancer and upper tract urothelial carcinoma

References

• Boormans JL, Zwarthoff EC. Limited funds for bladder cancer research and what can we do about it. Bladder Cancer. 2016;2(1):49–51.
   PubMedGoogle Scholar
• Bessa A, Maclennan S, Enting D, et al. Consensus in bladder cancer research priorities between patients and healthcare professionals using a four-stage modified Delphi method. Eur Urol. 2019;76(2):258–259.
   PubMed Web of Science ®Google Scholar
• Black PC. Seeking the molecular truth in bladder cancer: biology = genome×(transcriptome)2. Eur Urol. 2017;72(3):366–367.
   PubMed Web of Science ®Google Scholar
• https://sdb.socialstyrelsen.se/if_can/resultat.aspx.
   Google Scholar
• https://statistik.incanet.se/Urinblasecancer/.
   Google Scholar
• https://www-dep.iarc.fr/NORDCAN/SW/table11.asp?cancer=300&sex=0&stat=2&age_from=1&age_to=18&registry=752&sYear=2015&eYear=2016&submit=%A0%A0Utf%F6r%A0%A0.
   Google Scholar
• Koutros S, Decker KL, Baris D, et al. Bladder cancer risk associated with family history of cancer. Int J Cancer. 2021;148(12):2915–2923.
   PubMed Web of Science ®Google Scholar
• Joost P, Therkildsen C, Dominguez-Valentin M, et al. Urinary tract cancer in lynch syndrome; increased risk in carriers of MSH2 mutations. Urology. 2015;86(6):1212–1217.
   PubMed Web of Science ®Google Scholar
• Pylvänäinen K, Lehtinen T, Kellokumpu I, et al. Causes of death of mutation carriers in Finnish lynch syndrome families. Fam Cancer. 2012;11(3):467–471.
   PubMed Web of Science ®Google Scholar
• Rouprêt M, Babjuk M, Burger M, et al. European association of urology guidelines on upper urinary tract urothelial carcinoma: 2020 update. Eur Urol. 2021;79(1):62–79.
   PubMed Web of Science ®Google Scholar
• Le DT, Uram H, Wang BR, et al. PD-1 blockade in tumors with Mismatch-Repair deficiency. N Engl J Med. 2015;372(26):2509–2520.
   PubMed Web of Science ®Google Scholar
• Malmström PU, Skaaheim Haug E, Boström PJ, et al. Progress towards a Nordic standard for the investigation of hematuria: 2019. Scand J Urol. 2019;53(1):1–6.
   PubMed Web of Science ®Google Scholar
• Myrhøj T, Andersen M-B, Bernstein I. Screening for urinary tract cancer with urine cytology in Lynch syndrome and familial colorectal cancer. Fam Cancer. 2008;7(4):303–307.
   PubMed Web of Science ®Google Scholar
• Jin H, Lin T, Hao J, et al. A comprehensive comparison of fluorescence in situ hybridization and cytology for the detection of upper urinary tract urothelial carcinoma: a systematic review and Meta-analysis. Medicine (Baltimore)). 2018;97(52):e13859.,.
   PubMed Web of Science ®Google Scholar
• Berajoui MB, Aditya I, Herrera-Caceres J, et al. A prospective randomized controlled trial of irrigation "bag squeeze" to manage pain for patients undergoing flexible cystoscopy. J Urol. 2020;204(5):1012–1018.
   PubMed Web of Science ®Google Scholar
• Gunendran T, Briggs RH, Wemyss-Holden GD, et al. Does increasing hydrostatic pressure ("bag squeeze") during flexible cystoscopy improve patient comfort: a randomized, controlled study. Urology. 2008;72(2):255–258.
   PubMed Web of Science ®Google Scholar
• Rosenthal DL. The Paris system for reporting urinary cytology. 2016. http://www.springer.com/us/book/9783319228631.
   Google Scholar
• Janisch F, Shariat SF, Baltzer P, et al. Diagnostic performance of multidetector computed tomographic (MDCTU) in upper tract urothelial carcinoma (UTUC): a systematic review and Meta-analysis. World J Urol. 2020;38(5):1165–1175.
   PubMed Web of Science ®Google Scholar
• Voskuilen CS, Schweitzer D, Jensen JB, et al. Diagnostic value of 18F-fluorodeoxyglucose positron emission tomography with computed tomography for lymph node staging in patients with upper tract urothelial carcinoma. Eur Urol Oncol. 2020;3(1):73–79.
   PubMed Web of Science ®Google Scholar
• Brierly J, Gospodarowicz M, Wittekind C. TNM classification of malignant tumours. 8th ed. Oxford: UICC International Union Against Cancer; 2017.
   Google Scholar
• Fransen van de Putte EE, Otto W, Hartmann A, et al. Metric substage according to micro and extensive lamina propria invasion improves prognostics in T1 bladder cancer. Urol Oncol. 2018;36(8):361.e7-361–361.e13.
   Web of Science ®Google Scholar
• Liedberg F, Lauss M, Patschan O, et al. The importance of being grade 3: WHO 1999 versus WHO 2004 pathologic grading. Eur Urol. 2012;62(4):620–623.
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, Rodríguez O, Hernández V, et al. European association of urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC guidelines panel. Eur Urol. 2021;79(4):480–488.
   PubMed Web of Science ®Google Scholar
• Lobo N, Hensley PJ, Bree KK, et al. Updated European Association of Urology (EAU) prognostic factor risk groups overestimate the risk of progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin. Eur Urol Oncol. 2021.doi: https://doi.org/10.1016/j.euo.2021.11.006.
   Google Scholar
• Gil M, Guerra J, Andrade V, et al. The impact of multidisciplinary team conferences in urologic cancer in a tertiary hospital. Int Urol Nephrol. 2021;53(1):41–47.
   PubMed Web of Science ®Google Scholar
• Gordetsky J, Collingwood R, Lai WS, et al. Second opinion expert pathology review in bladder cancer: implications for patient care. Int J Surg Pathol. 2018;26(1):12–17.
   PubMed Web of Science ®Google Scholar
• Wayment RO, Bourne A, Kay P, et al. Second opinion pathology in tertiary care of patients with urologic malignancies. Urol Oncol. 2011;29(2):194–198.
   PubMed Web of Science ®Google Scholar
• Traboulsi SL, Brimo F, Yang Y, et al. Pathology review impacts clinical management of patients with T1-T2 bladder cancer. Can Urol Assoc J. 2017;11(6):188–193.
   PubMed Web of Science ®Google Scholar
• Luchey AM, Manimala NJ, Dickinson S, et al. Change in management based on pathologic second opinion among bladder cancer patients presenting to a comprehensive cancer center: implications for clinical practice. Urology. 2016;93:130–134.
   PubMed Web of Science ®Google Scholar
• Kurpad R, Kim W, Rathmell WK, et al. A multidisciplinaryapproach to the management of urologic malignancies: does it influence diagnostic and treatment decisions? Urol Oncol. 2011;29:78–82.
   PubMed Web of Science ®Google Scholar
• Van Rhijn BW, van der Kwast TH, Kakiashvili DM, et al. Pathological stage review is indicated in primary pT1 bladder cancer. BJU Int. 2009;106(2):206–211.
   PubMed Web of Science ®Google Scholar
• Tay LJ, Chatterton K, Colemeadow J, et al. Improving management of upper tract urothelial carcinoma. BJU Int. 2020;126(1):5–6.
   PubMed Web of Science ®Google Scholar
• Onishi T, Sugino Y, Shibahara T, et al. Randomized controlled study of the efficacy and safety of continuous saline bladder irrigation after transurethral resection for the treatment of non-muscle-invasive bladder cancer. BJU Int. 2017;119(2):276–282.
   PubMed Web of Science ®Google Scholar
• ) Mariappan P, Finney SM, Head E, et al. Good quality white-light transurethral resection of bladder tumours (GQ-WLTURBT) with experienced surgeons performing complete resections and obtaining detrusor muscle reduces early recurrence in new non-muscle-invasive bladder cancer: validation across time and place and recommendation for benchmarking. BJU Int. 2012;109:1666–1673.
   PubMedGoogle Scholar
• Van der Meijden AP, Sylvester RJ, Oosterlinck W, et al. EORTC Genito-Urinary tract cancer group. Maintenance bacillus Calmette-Guérin for ta, T1 bladdertumours is not associated with increased toxicity: results from a EORTC phase III trial. Eur Urol. 2003;44(4):429–434.
   PubMed Web of Science ®Google Scholar
• Kamat AM, Sylvester RJ, Böhle A, et al. Definitions, end points, and clinical trial designs for Non-muscle-Invasive bladder cancer: recommendations from the international bladder cancer group. J Clin Oncol. 2016;34(16):1935–1944.
   PubMed Web of Science ®Google Scholar
• Tan WS, Panchal A, Buckley L, et al. Radiofrequency-induced thermo-chemotherapy effect versus a second course of bacillus Calmette-Guérin or institutional standard in patients with recurrence of non-muscle-invasive bladder cancer following induction or maintenance bacillus Calmette-Guérin therapy (HYMN): a phase III, open-label, randomised controlled trial. Eur Urol. 2019;75(1):63–71.
   PubMed Web of Science ®Google Scholar
• Steinberg RL, Thomas LJ, Brooks N, et al. Multi-Institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer. J Urol. 2020;203(5):902–909.
   PubMed Web of Science ®Google Scholar
• Peyronnet B, Seisen T, Dominguez-Escrig JL, et al. Oncological outcomes of laparoscopic nephroureterectomy versus open radical nephroureterectomy for upper tract urothelial carcinoma: an European Association of Urology guidelines systematic review. Eur Urol Focus. 2019;5(2):205–223.
   PubMedGoogle Scholar
• Simone G, Papalia R, Guaglianone S, et al. Laparoscopic versus open nephroureterectomy: perioperative and oncologic outcomes from a randomised prospective study. Eur Urol. 2009;56(3):520–526.
   PubMed Web of Science ®Google Scholar
• Sui W, Wallis CJD, Luckenbaugh AN, et al. The impact of hospital volume on short-term and long-term outcomes for patients undergoing radical nephroureterectomy for upper tract urothelial carcinoma. Urology. 2021;147:135–142.
   PubMed Web of Science ®Google Scholar
• Birtle A, Johnson M, Chester J, et al. Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. Lancet. 2020;395(10232):1268–1277.
   PubMed Web of Science ®Google Scholar
• O'Brien T, Ray E, Singh R, et al. Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicenter, randomized clinical trial of single postoperative intravesical dose of mitomycin C. Eur Urol. 2011;60(4):703–710.
   PubMed Web of Science ®Google Scholar
• Ito A, Shintaku I, Satoh M, et al. Prospective randomized phase II trial of a single early intravesical instillation of pirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma: the THP monotherapy study group trial. J Clin Oncol. 2013;31(11):1422–1427.
   PubMed Web of Science ®Google Scholar
• Seisen T, Peyronnet B, Dominguez-Escrig JL, et al. Oncologic outcomes of kidney-sparing surgery versus radical nephroureterectomy for upper tract urothelial carcinoma: a systematic review by the EAU non-muscle invasive bladder cancer guidelines panel. Eur Urol. 2016;70(6):1052–1068.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Cao Z, Xu C, et al. Solifenacin is able to improve the irritative symptoms after transurethral resection of bladder tumors. Urology. 2014;84(1):117–121.
   PubMed Web of Science ®Google Scholar
• Sun K, Wang D, Wu G, et al. Mirabegron improves the irritative symptoms caused by BCG immunotherapy after transurethral resection of bladder tumors. Cancer Med. 2021;10(21):7534–7541. Sep 21. Epub ahead of print.
   PubMed Web of Science ®Google Scholar
• Bobjer J, Hagberg O, Aljabery F, et al. Bladder cancer recurrence in primary papillary urothelial neoplasm of low malignant potential (PUNLMP) compared to G1 WHO 1999: a population-based study scand. J Urol. 2022;56:14–18.
   Web of Science ®Google Scholar
• Hentschel AE, van Rhijn BWG, Bründl J, et al. Papillary urothelial neoplasm of low malignant potential (PUN-LMP): still a meaningful histo-pathological grade category for ta, noninvasive bladder tumors in 2019? Urol Oncol. 2020;38(5):440–448.
   PubMed Web of Science ®Google Scholar
• Lammers RJ, Hendriks JC, Rodriguez Faba OR, et al. Prediction model for recurrence probabilities after intravesical chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer, including external validation. World J Urol. 2016;34(2):173–180.
   PubMed Web of Science ®Google Scholar